NASDAQ:QNTM Quantum Biopharma 3/28/2025 Earnings Report $11.55 -0.67 (-5.48%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$11.73 +0.18 (+1.56%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Quantum Biopharma EPS ResultsActual EPS-$2.89Consensus EPS -$0.80Beat/MissMissed by -$2.09One Year Ago EPSN/AQuantum Biopharma Revenue ResultsActual RevenueN/AExpected Revenue$0.92 millionBeat/MissN/AYoY Revenue GrowthN/AQuantum Biopharma Announcement DetailsQuarterDate3/28/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsQuantum Biopharma's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Quantum Biopharma Earnings HeadlinesQuantum BioPharma Increases Crypto Holdings To $4.5 Mln For Strategic GrowthMay 21, 2025 | nasdaq.comQuantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple SclerosisMay 20, 2025 | globenewswire.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.May 25, 2025 | Timothy Sykes (Ad)Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000May 19, 2025 | globenewswire.comQuantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare ConferenceMay 16, 2025 | globenewswire.comQuantum BioPharma Completes Dosing in 90-Day Toxicity Studies for Multiple Sclerosis Drug Lucid-21-302, Advancing Toward IND SubmissionMay 13, 2025 | nasdaq.comSee More Quantum Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email. Email Address About Quantum BiopharmaQuantum Biopharma (NASDAQ:QNTM) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases, including Lucid-MS, a first-in-class small molecule drug candidate designed to promote remyelination in patients with Multiple Sclerosis (MS).Written by Jeffrey Neal JohnsonView Quantum Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout? Upcoming Earnings PDD (5/27/2025)AutoZone (5/27/2025)Bank of Nova Scotia (5/27/2025)NVIDIA (5/28/2025)Synopsys (5/28/2025)Bank of Montreal (5/28/2025)Salesforce (5/28/2025)Haleon (5/28/2025)Costco Wholesale (5/29/2025)Marvell Technology (5/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.